Vipergen, a leading provider of small-molecule drug discovery services based on DNA-encoded library (DEL) technologies, announced today the signing of a drug discovery service agreement with Anavo Therapeutics. Under the terms of the agreement, Vipergen will apply its proprietary high-fidelity DNA-encoded library
| COPENHAGEN, Denmark, May 17, 2021 /PRNewswire/ -- Vipergen, a leading provider of small-molecule drug discovery services based on DNA-encoded library (DEL) technologies, announced today the signing of a drug discovery service agreement with Anavo Therapeutics. Under the terms of the agreement, Vipergen will apply its proprietary high-fidelity DNA-encoded library (DEL) technology platforms to provide novel small-molecule drug leads against selected Anavo discovery targets. Financial details of the agreement were not disclosed. “Vipergen’s innovative solutions to DNA-encoded libraries are valuable components for ramping up our proprietary drug discovery efforts against a selected portfolio of innovative targets,” said Birgit Zech, PhD, Chief Executive Officer of Anavo. “We look forward to partnering with Vipergen to jump-start Anavo’s proprietary drug development efforts as we continue to build a robust and reliable platform for phosphatase drug discovery against all valuable targets in the space.” “We are excited to be selected by Anavo, a new company focused on unlocking the full therapeutic potential of human phosphatase biology to develop new cancer treatments,” said Nils Hansen, PhD, Chief Executive Officer of Vipergen. “Phosphatases are a rich target space that has been considered undruggable for decades. We look forward to applying our DNA-encoded library technologies to rapidly deliver high-quality hits and leads as part of Anavo’s systematic approach to discovering and developing small-molecule modulators of phosphatase activity.” About Vipergen ApS Contact:
SOURCE Vipergen |
View original content:
